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Background: Cardiovascular disease (CVD) is the leading cause of death and associates with multiple risk factors.
Herb medicines have been used to treat CVD long ago in china and several natural products or derivatives (e.g.,
aspirin and reserpine) are most common drugs all over the world. The objective of this work was to construct a
systematic database for drug discovery based on natural products separated from CVD-related medicinal herbs and
to research on action mechanism of herb medicines.
Description: The cardiovascular disease herbal database (CVDHD) was designed to be a comprehensive resource for
virtual screening and drug discovery from natural products isolated from medicinal herbs for cardiovascular-related
diseases. CVDHD comprises 35230 distinct molecules and their identification information (chemical name, CAS registry
number, molecular formula, molecular weight, international chemical identifier (InChI) and SMILES), calculated molecular
properties (AlogP, number of hydrogen bond acceptor and donors, etc.), docking results between all molecules and
2395 target proteins, cardiovascular-related diseases, pathways and clinical biomarkers. All 3D structures were optimized
in the MMFF94 force field and can be freely accessed.
Conclusions: CVDHD integrated medicinal herbs, natural products, CVD-related target proteins, docking results, diseases
and clinical biomarkers. By using the methods of virtual screening and network pharmacology, CVDHD will provide a
platform to streamline drug/lead discovery from natural products and explore the action mechanism of medicinal herbs.
CVDHD is freely available at http://pkuxxj.pku.edu.cn/CVDHD.
Keywords: Cardiovascular disease, Drug discovery, Network pharmacology, Molecular docking, Virtual screening, Herbal
formula, Natural products, Medicinal herbs, Traditional Chinese medicineBackground
Natural products have been an important source for
drug/lead discovery [1,2]. More than half of FDA-
approved drugs are natural products or derivatives [3].
The most important approach in current drug discov-
ery is through screening. However, traditional com-
binatorial chemistry libraries generally show limited
structural diversity [4]. Through the natural selection
process, natural products have vast diversities both in
chemical space and pharmacological space [5-7]. High-
throughput screening (HTS) in silico is used to reduce
the number of chemicals to be tested in vitro and vivo.
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reproduction in any medium, provided the orapproach to identify chemicals that could fit into the
active site of target proteins. Therefore the virtual
screening based on natural product database is a prom-
ising approach for drug discovery, especially for com-
plex diseases such as cardiovascular disease.
Cardiovascular disease is regarded to be the main
cause of death worldwide [8]. As a complex disease,
CVD is the consequence of multiple pathogenic factors
and reflects the altered interactions of many intercon-
nected genes and gene products [9]. How to effectively
and efficiently reverse these inappropriate interactions
in a sick state is a critical problem. However, most
drugs for CVD were designed to target a specific target
and cannot be very effective [10-12]. In contrast, drugs
which target multiple targets will have maximal efficacy
and minimal adverse effects [13]. Polypharmacology
and network pharmacology are useful approaches for
understanding the mechanism and evaluating thetd. This is an open access article distributed under the terms of the Creative
commons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sign and development of drugs with higher success rate
[14-18]. Meanwhile, biological pathways of diseases or
biological process are important networks and usually
associate with clinical biomarkers [19]. By investigating
the effects of compounds on the biological pathway
network, researchers can easily evaluate the potency of
compounds and thus move basic biological discoveries
into the clinic applications.
The herbal medicines which contain biologically active
natural products for CVD have been used for thousands
of years in China. However, the ingredients are too com-
plex (usually hundreds of compounds) and the biological
mechanisms of herbs are not yet understood clearly
[14,16,18,20]. Along with the progress of network
pharmacology and the explosive growth of biomedical
data, the analysis of action mechanisms of medicinal
herbs at the systems level becomes possible [5,15,21-23].
Therefore, we constructed the cardiovascular disease
herbal database (CVDHD) that was implemented based
on natural products-target proteins interactions and in-
tegration of multi-level data to promote the drug discov-
ery from natural products and explore the molecular
basis of polypharmacology of medicinal herbs for CVD.
CVDHD will also provide an efficient platform for re-
search on traditional Chinese medicine (TCM) and
translational research in complementary and alternative
medicine.
Construction and content
CVDHD comprises six data entities covering medicinal
herbs, natural products, target proteins, docking re-
sults between all molecules and target proteins, dis-












Figure 1 Database schema and search flow chart.herbs (Chinese name, Latin name and pharmacological
effects) for cardiovascular-related diseases were col-
lected from Chinese Herbalism [24] and Chinese
Pharmacopoeia [25]. The structures and identification
information (chemical name, CAS registry number,
molecular formula, molecular weight and information
of references) of natural products contained in the me-
dicinal herbs were retrieved from CHDD [26] and
UNPD [5] which were both developed by our lab in re-
cent years. The absolute configuration of each mol-
ecule was generated by Open Babel [27] and the
duplicates were deleted according to InChIKey. The
molecular properties (AlogP, number of hydrogen
bond acceptor and donors, etc.) were calculated by
Discovery Studio.
There were two main groups of target proteins in
CVDHD. One was the drug targets retrieved from Drug-
Bank [28], another was the other proteins of human.
Each protein had X-ray or NMR ligand-protein complex
structures in RCSB protein data bank (http://www.rcsb.
org/pdb/home/home.do). These structures were down-
loaded and treated to be suitable for molecular docking
by Autodock4 [29] according to the procedure described
previously [5]. For each protein, the binding site was
defined as a 40 × 40 × 40 Å cube centered on the occupied
space of the original ligand with a spacing of 0.375 Å be-
tween the grid points. The parameters of autodock4 were
listed in Additional file 1. The docking score of autodock4
was chosen to evaluate the binding affinity according to
binding free energy.
The information of diseases and clinical biomarkers
related to CVD was collected from KEGG [30], TTD
[31] and literatures manually. Finally, the data was
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was deployed to an Apache Tomcat server (PHP 5.1.6
and HTTPD 2.2.3). CVDHD can be accessed via the
internet. Moreover, the API for Cytoscape was reserved
to meet the future demands. Therefore, CVDHD can be
applied seamlessly to the network pharmacology ana-




CVDHD had a powerful and intuitive web interface. The
web pages were divided into five sections (Home, Intro-
duction, Browse, Search and Download). A concise
retrieval system for natural products was available on
the homepage. User can search exactly by its identifica-
tion information or get a group of compounds by the
Latin name of medicinal herb. The introduction page
described the database design and main functions. The
browse pages contained five lists of medicinal herbs,
molecules, proteins, diseases and biomarkers. The vari-
ous data retrievals of drug discovery and network
pharmacology can be achieved on search pages. The
download page contained several links for download.
Lead compound discovery
The lead generation is a crucial step in drug discovery
[32]. Nowadays, HTS has become the major paradigm
for lead discovery from chemical libraries [32,33].
Lipinski’s “rule of five” (molecular weight less than
500 Da, hydrogen bond acceptors less than 10, hydro-
gen bond donors less than 5, octanol-water partition co-
efficient less than five) [34] was a simple but powerful
rule to estimate the possibility of converting a com-
pound into a drug. CVDHD can easily screen out the
molecules which obey “rule of five” or other customized
thresholds. For example, user can retrieve the poten-
tially bioactive compounds from Panax ginseng (one of
the most important medicinal herbs used as a tonic for
restoration [35]) after entering the Latin name of this
herb and thresholds of molecular properties on the ad-
vanced search webpage. The output of this query will be
a table containing the molecular information and down-
load link of each compound.
Moreover, if the target proteins of a disease were clear,
the receptor-based drug design will accelerate the pro-
gress of drug discovery [36]. The HTS results between
all molecules and all target proteins were stored in
CVDHD and user can access data by simply typing four
parameters: the Uniprot accession number of the target
protein, the thresholds of docking score (pKi), the top
percentage of rank of docking score and the logic value
of whether the docking score of compounds was higher
than that of original ligand in the X-ray or NMRstructure of the target protein (0 or 1). It may save a lot
of time for users in the process of virtual screening.
Network pharmacology research
Complex diseases such as CVD and diabetes are caused
by a variety of genetic and environmental factors [37].
The modern drugs (magic bullets) which act on single
target cannot treat complex diseases effectively [38-41].
Therefore, Hopkins AL [15,22] proposed network
pharmacology to explore the action mechanism of
drugs in the context of biological networks such as bio-
logical pathway, gene regulatory network, protein-
protein interaction network, drug-target network, etc.
The drug-target network (DTN) and its derivatives
(drug-drug network (DDN) and target-target network
(TTN)) could have important implications in under-
standing the mechanism and harnessing the vast
amount of data from HTS [42-45].
The drug-target network was constructed according
to the various binding data between molecules and tar-
get proteins. However, there were only a small portion
(less than 2%) of natural products which binding data
has been reported [5]. Thus, CVDHD used molecular
docking to calculate the binding affinity between all
molecules and 2395 target proteins. Based on CVDHD,
comprehensive research on the mechanism of the medi-
cinal herbs ranging from the level of herbal formula to
protein-compound interaction can be achieved. Moreover,
user can retrieve all target proteins relating to a pathway
of a disease or biological process and finally find out the
potential interactions between molecules and proteins to
construct DTN, DDN and TTN to unveil the mechanism
of TCM. CVDHD may bridge the gap between TCM and
modern drugs based on system-level analysis.
Case study: platelet aggregation pathway based lead
discovery
Platelet aggregation plays an important role in arterial
thrombosis in coronary heart disease [46]. How to regu-
late the platelet aggregation of CVD patients is one of
the keys of successful treatment. The pathway of platelet
aggregation comprised nineteen target proteins [19]. If a
compound can block one of these proteins, the platelet
aggregation will be inhibited to some extent. That is, the
more inhibition of targets, the more effective the com-
pound would be [19,47].
We retrieved the potentially active compounds from
CVDHD with the following parameters: the thresholds of
docking score, the top percentage of rank of docking score
were set to 7.0 and 0.10, respectively. Meanwhile, the
docking score of compounds should be higher than that of
original ligand. The drug-target network (Additional file 2:
Table S1) was constructed by linking the compound and
target protein if the docking score exceeded the
Table 1 Top potential compounds for inhibition of platelet aggregation according to degree centrality of drug-target
network
Rank Compound Degree CAS NO. Chemical name
1 CVDHD016293 6 62218-13-7 (+)-α-viniferin
2 CVDHD027110 6 N/A hypericinate
3 CVDHD007020 6 54352-30-6 tricrotonyltetramine
4 CVDHD012997 6 N/A blumeanine
5 CVDHD001236 5 N/A kadlongilactone B
6 CVDHD012285 5 225662-66-8 hypericin radical cation
7 CVDHD002703 5 50838-55-6 trisjuglone
8 CVDHD032784 5 55954-61-5 pseudohypericine
9 CVDHD029497 5 7034-04-0 tricrotonyltetramin
10 CVDHD002390 4 N/A 20(R)-21,24-Cyclo-3beta,25-dihydroxyldammar-23(24)-en-21-one
11 CVDHD014854 4 N/A longipedlactone F
12 CVDHD034764 4 N/A celastroline B alpha
13 CVDHD010515 4 123522-98-5 isowithametelin
14 CVDHD014739 4 N/A eremodimer B
15 CVDHD025068 4 N/A bismorphine B
16 CVDHD017384 4 1253379-22-4 dievodiamine
17 CVDHD021374 4 N/A lycochinine B
18 CVDHD025464 4 511-98-8 solasodanol
19 CVDHD019403 4 129748-10-3 incarvillateine
20 CVDHD019431 4 548-04-9 hypericin
21 CVDHD029988 4 129225-31-6 aminopropylcanavalmine
22 CVDHD009071 4 77646-14-1 3β,17α-Cinchophylline
23 CVDHD015834 4 N/A bismorphine A
24 CVDHD011497 4 N/A dihydro-18,19 3β,17β cinchophylline
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draw the DTN and calculate the degree and betweenness
centrality of each node (compound or target). The larger
degree and the higher betweenness, the more effect on the
inhibition of platelet aggregation of that compound will be
according to the network theory. Table 1 listed the top
rank of potential compounds which may be the lead com-
pounds for inhibition of platelet aggregation for further
study. However, it is a simple model to use degree central-
ity to evaluate the efficacy of natural products. Users can
use other models to predict the efficacy in the context of
drug-target network.
Conclusions
CVDHD is aimed to integrate medicinal herbs, natural
products, CVD-related target proteins, docking results,
diseases and clinical biomarkers to be a comprehensive
database for drug discovery from natural products iso-
lated from medicinal herbs. First, CVDHD is a chem-
ical library of natural products and ready for virtual
screening. All 3D structures of natural products andinformation of binding site of target proteins can be
accessed on the website. Second, drug/lead discovery
for single target or a group of proteins related to a dis-
ease or biological process can be achieved. Finally, it is
also a research platform for network pharmacology of
medicinal herbs and TCM. The molecule and herb
search can be applied to get compounds contained in
herbs. Moreover, CVDHD is useful for study of net-
work pharmacology of CVD-related natural products.
The herbs contain a variety of ingredients and the com-
pounds would interact with multiple cellular targets.
By identifying the associations between bioactive
compounds and cellular target proteins, CVDHD may
bridge the gap between the systems level (herbal for-
mula or medicinal herb) and molecular biology (com-
pounds and proteins).
Availability and requirements
CVDHD is freely available at http://pkuxxj.pku.edu.cn/
CVDHD and there are no restrictions for academic use.
The database will be updated annually.
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Additional file 1: Autodock4 parameters.
Additional file 2: Table S1. Drug-target network of potential lead
compounds and target proteins of platelet aggregation pathway.
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